🔗 Permalink

Inventor profile of:

John S. Petersen

City:

Acton, Massachusetts

Country:

United States

Published Applications:

Last publication date:

2026-03-19

Top Assignees for applications by John S. Petersen

The entities that hold a legal rights for patent applications filed by inventor Petersen John S.:

SynDevRx, Inc. 16 Cambridge, MA United States
Genzyme Corporation 6 Cambridge, MA United States
TRANSPORT PHARMACEUTICALS, INC. 3 Framingham, MA United States
Genzyme Corporation 3 Waltham, MA United States
Genzyme Corporation 1 Boston, MA United States
SynDecRx, Inc. 1 Cambridge, MA United States
Nitric Biotherapeutics, Inc. 1 Bristol, PA United States
SynDevRX 1 Cambridge, MA United States
GLAXOSMITHKLINE UK LIMITED 1 Ware, United Kingdom
GelTex Pharmaceuticals, Inc. 1 Waltham, MA United States

Recent patent applications by Petersen John S.

John S. Petersen from Acton, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-03-19

US20260076960A1

Human necessities

METAP2 INHIBITORS AND METHODS OF TREATING OBESITY

#2 | 2025-09-18

US20250288606A1

Human necessities

POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF

#3 | 2023-06-01

US20230165892A1

Human necessities

POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF

#4 | 2023-02-16

US20230048989A1

Human necessities

METAP2 INHIBITORS AND METHODS OF TREATING OBESITY

#5 | 2021-05-06

US20210128607A1

Human necessities

POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF

#6 | 2020-05-21

US20200155545A1

Human necessities

MetAP2 inhibitors and methods of treating obesity

#7 | 2019-05-23

US20190151353A1

Human necessities

Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof

#8 | 2018-10-11

US20180291010A1

Chemistry; metallurgy

Fumagillol derivatives and polymorphs thereof

#9 | 2018-09-27

US20180271856A1

Human necessities

METAP2 inhibitors and methods of treating obesity

#10 | 2018-01-11

US20180008630A1

Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

#11 | 2017-11-16

US20170326135A1

Human necessities

METAP2 inhibitors and methods of treating obesity

#12 | 2017-09-14

US20170258925A1

Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

#13 | 2017-07-20

US20170202872A1

Human necessities

Direct compression polymer tablet core

#14 | 2017-06-15

US20170166556A1

Chemistry; metallurgy

Fumagillol derivatives and polymorphs thereof

#15 | 2017-02-02

US20170028014A1

Human necessities

MetAP2 inhibitors and methods of treating obesity

#16 | 2016-12-01

US20160346244A1

Human necessities

METAP2 inhibitors and methods of treating obesity

#17 | 2016-09-08

US20160256483A1

Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

#18 | 2016-06-30

US20160184345A1

Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

#19 | 2015-12-31

US20150374657A1

Human necessities

METAP2 inhibitors and methods of treating obesity

#20 | 2015-05-21

US20150141580A1

Human necessities

OPTIMIZED DRUG CONJUGATES

#21 | 2015-02-26

US20150056278A1

Human necessities

Direct compression polymer tablet core

#22 | 2014-10-16

US20140308235A1

Human necessities

METAP2 inhibitors and methods of treating obesity

#23 | 2013-08-22

US20130216494A1

Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

#24 | 2013-05-30

US20130137831A1

Human necessities

OPTIMIZED DRUG CONJUGATES

#25 | 2012-12-20

US20120322894A1

Human necessities

Direct Compression Polymer Tablet Core

#26 | 2011-12-01

US20110294952A1

Human necessities

Optimized Drug Conjugates

#27 | 2010-10-21

US20100266526A1

Human necessities

Combination therapy for treating hypercholesterolemia

#28 | 2010-03-18

US20100068167A1

Human necessities

Low salt forms of polyallylamine

#29 | 2009-12-29

US10025184

Combination therapy for treating hypercholesterolemia

#30 | 2009-11-26

US20090291135A1

Human necessities

Direct compression polymer tablet core

#31 | 2009-06-02

US10125684

Low salt forms of polyallylamine

#32 | 2008-02-28

US20080051692A1

Human necessities

APPLICATOR CARTRIDGE FOR AN ELECTROKINETIC DELIVERY SYSTEM FOR SELF ADMINISTRATION OF MEDICAMENTS

#33 | 2007-10-04

US20070233048A1

Human necessities

Combination cartridge and device for electrokinetic delivery of medicament to a treatment site

#34 | 2007-08-16

US20070190021A1

Human necessities

Poly(diallylamine)-based bile acid sequestrants

#35 | 2007-08-09

US20070185432A1

Human necessities

ELECTROKINETIC SYSTEM AND METHOD FOR DELIVERING METHOTREXATE

#36 | 2006-10-24

US10647665

Poly(diallylamine)-based bile acid sequestrants

#37 | 2006-02-16

US20060034914A1

Human necessities

Direct compression polymer tablet core

#38 | 2005-11-24

US20050260236A1

Human necessities

Direct compression polymer tablet core

InventorID:

400900 ⎘